Tempo Therapeutics Raises $14.5 Million
Tempo Therapeutics, a biotechnology and tissue engineering company based in San Diego, California, has announced a successful funding round, securing $14.5 million on September 18, 2026. The company is known for its innovative approach to accelerating patient recovery processes through advanced biotechnology solutions.
Investors and Leadership
The recent funding round did not disclose a lead investor but saw participation from several notable investment firms, including Galaxy Sirius Partners, Johnson & Johnson Innovation, Gideon Strategic Partners, Mesa Verde Venture Partners, and YK Bioventures. Westbrook Weaver, the founder and CEO of Tempo Therapeutics, continues to lead the company in its mission to enhance recovery outcomes for patients.
Planned Use of Funds
While specific allocations of the new funds have not been detailed, the investment will likely support Tempo Therapeutics in further developing its biotechnology solutions, potentially expanding its research and development capabilities, and scaling its operations to reach a broader market.
Tempo Therapeutics is positioning itself as a significant player in the field of biotechnology, focusing on innovations that aim to improve patient care and recovery times. The latest funding round underscores investor confidence in the company's potential to make impactful advancements in the healthcare sector.